Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma

Receiving Model for End-Stage Liver Disease (MELD) exception status for hepatocellular carcinoma (HCC) improves wait-list survival and probability of liver transplantation (LT). We aim to evaluate etiology-specific disparities in MELD exception, LT wait-list times, and post-LT outcomes among patients with HCC listed for LT. Using United Network for Organ Sharing 2004-2013 data, we evaluated adults (age>18 years) with HCC secondary to hepatitis C virus (HCV), nonalcoholic steatohepatitis (NASH), alcoholic cirrhosis (EtOH), hepatitis B virus (HBV), combined EtOH/HCV, and combined HBV/HCV. Multivariate regression models evaluated etiology-specific odds of active exception, probability of receiving LT, and post-LT survival. In total, 10,887 HCC patients were listed for LT from 2004 to 2013. Compared with HCV-HCC patients (86.8%), patients with NASH-HCC (67.7%), and EtOH-HCC (64.4%) had a lower proportion with active MELD exception (P<0.001). On multivariate regression, NASH-HCC and EtOH-HCC patients had significantly lower odds of active MELD exception compared with HCV-HCC (NASH-HCCodds ratio [OR], 0.73; 95% confidence interval [CI], 0.58-0.93; P=0.01; EtOH-HCCOR, 0.72; 95% CI, 0.59-0.89; P=0.002). Compared with HCV-HCC patients, NASH-HCC (HR, 0.83; 95% CI 0.76-0.90; P<0.001), EtOH-HCC (HR, 0.88; 95% CI 0.81-0.96; P=0.002), and EtOH/HCV-HCC (HR, 0.92; 95% CI 0.85-0.99; P=0.03) were less likely to receive LT if they had active exception. Without active exception, these discrepancies were more significant (NASH-HCCHR, 0.22; 95% CI, 0.18-0.27; P<0.001; EtOH-HCCHR, 0.22; 95% CI, 0.18-0.26; P<0.001; EtOH/HCV-HCCHR, 0.26; 95% CI, 0.22-0.32; P<0.001). In conclusion, among US adults with HCC listed for LT, patients with NASH-HCC, EtOH-HCC, and EtOH/HCV-HCC were significantly less likely to have active MELD exception compared with HCV-HCC, and those without active exception had a lower likelihood of receiving LT. More research is needed to explore why NASH-HCC patients were less likely to have active MELD exception. Liver Transplantation 22 1356-1366 2016 AASLD.